| Default | Sensitivity 1 | Sensitivity 3 | |||||
---|---|---|---|---|---|---|---|---|
VF ≥ 200 cps/mL | VF ≥ 200 cps/mL | VF ≥ 1,000 cps/mL | VF ≥ 10,000 cps/mL | |||||
Multivariable HR (95% CI) | p-value | Multivariable HR (95% CI) | p-value | Multivariable HR (95% CI) | p-value | Multivariable HR (95% CI) | p-value | |
Monitoring randomisation | ||||||||
 LCM | 1.00 | - | 1.00 | - | 1.00 | - | 1.00 | - |
 CDM | 1.11 (0.93 – 1.34) | 0.25 | 1.16 (0.98 – 1.38) | 0.09 | 1.14 (0.94 – 1.37) | 0.19 | 1.18 (0.96 – 1.45) | 0.11 |
Gender | ||||||||
 Male | 1.00 | - | 1.00 | - | 1.00 | - | 1.00 | - |
 Female | 0.79 (0.65 – 0.95) | 0.01 | 0.84 (0.70 – 1.01) | 0.06 | 0.78 (0.64 – 0.95) | 0.01 | 0.77 (0.62 – 0.95) | 0.02 |
Initial ART | ||||||||
 TDF | 1.00 | <0.0001 | 1.00 | <0.0001 | 1.00 | <0.0001 | 1.00 | <0.0001 |
 NVP | 0.48 (0.38 – 0.62) | - | 0.49 (0.39 – 0.62) | - | 0.49 (0.38 – 0.63) | - | 0.50 (0.38 – 0.65) | - |
 ABC | 1.27 (1.02 – 1.59) | - | 1.23 (0.99 – 1.52) | - | 1.23 (0.97 – 1.55) | - | 1.00 (0.76 – 1.31) | - |
TB in 12 months prior to enrolment | 1.07 (0.86 – 1.33) | 0.52 | 1.07 (0.88 – 1.32) | 0.47 | 1.08 (0.86 – 1.36) | 0.49 | 1.15 (0.91 – 1.46) | 0.24 |
Age (per 10 years older) | 0.73 (0.64 – 0.84) | <0.0001 | 0.77 (0.68 – 0.88) | <0.0001 | 0.70 (0.61 – 0.81) | <0.0001 | 0.69 (0.60 – 0.80) | <0.0001 |
Baseline CD4 (per 100 cells/mm3 higher) | 0.64 (0.54 – 0.75) | <0.0001 | 0.67 (0.57 – 0.78) | <0.0001 | 0.60 (0.50 – 0.72) | <0.0001 | 0.52 (0.43 – 0.64) | <0.0001 |
Baseline viral load (log10 copies/mL) | 1.01 (0.84 – 1.22) | 0.89 | 0.99 (0.83 – 1.18) | 0.91 | 1.02 (0.84 – 1.24) | 0.82 | 1.02 (0.82 – 1.25) | 0.88 |
Adherence in previous 48 weeksa (per 10% higher) | 0.89 (0.84 – 0.94) | <0.0001 | 0.90 (0.85 – 0.94) | <0.0001 | 0.89 (0.84 – 0.94) | <0.0001 | 0.88 (0.82 – 0.94) | <0.0001 |